Orphanet: Simple search

Search for a clinical trial

Other search option(s)

207 Result(s)

National clinical trial(s)

First-MIND: Phase Ib, Open-label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) - AT Institution: Information not provided - AT

ESCALADE: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Subjects <65 Years With Previously Untreated Non-Germinal Center DLBCL - AT Institution: Information not provided - AT

Phase I, Open Label, Multicenter, Dose Escalation Study of CD19-specific CAR-T Cells in Adult Patients With CLL/SLL and DLBCL - AT Institution: Information not provided - AT

A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-Cell Lymphoma Post-autologous Hematopoietic Stem-cell Transplantation - BE UZ Leuven - Campus Gasthuisberg Department of Hematology

A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART2019.1 in Patients With Relapsed or Resistant CD20 and CD19 Positive B-NHL Universitätsklinikum Köln Klinik I für Innere Medizin

R-CHOEP-brut: Ibrutinib and Standard Immuno-Chemotherapy (R-CHOEP-14) in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma (Phase II) DE Universitätsklinikum Münster Medizinische Klinik und Poliklinik A

DSHNHL 2004-3 (UNFOLDER 21/14 Study): Phase III randomized study of immunochemotherapy Rituximab-CHOP with or without radiotherapy in patients with aggressive, B-Cell Non-Hodgkin's Lymphoma Universitätsklinikum des Saarlandes Klinik für Innere Medizin I

DSHNHL 2004-2 (FLYER): Randomized Phase III Study: 6 x anti-CD20-antibody Rituximab + 6 x CHOP-21 vs. 6 x anti-CD20-antibody Rituximab + 4 x CHOP-21 in patients aged 18-60 years with aggressive CD20 positive B-Cell Lymphoma - DE Universitätsklinikum des Saarlandes Klinik für Innere Medizin I

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL) - ES Institution: Information not provided - ES

ESCALADE: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Subjects <65 Years With Previously Untreated Non-Germinal Center DLBCL - ES Institution: Information not provided - ES

A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-Cell Lymphoma Post-autologous Hematopoietic Stem-cell Transplantation - CH Institution: Information not provided - CH

ZUMA-7: A Phase 3, Randomized, Open-Label Study Evaluating Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma - AT Medizinische Universität Graz Klinische Abteilung für Hämatologie

SADAL: A Phase 2b Open-label, Randomized, Two-arm Study comparing high and low doses of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - AT Medizinische Universität Innsbruck Universitätsklinik für Innere Medizin V - Hämatologie und Onkologie

R-CPOP as first line therapy for elderly patients with DLBCL and for patients with limited cardiac function with DLBCL (phase 2) - AT Institution: Information not provided - AT

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas - AT Institution: Information not provided - AT

A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma - AT Institution: Information not provided - AT

Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 Directed CAR T-Cell Therapy (Phase II-III) - AT Institution: Information not provided - AT

PORTIA: Phase Ib Study of Tisagenlecleucel in Combination With Pembrolizumab in Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) Patients - AT Institution: Information not provided - AT

TRANSCENDWORLD: A Phase 2, Single-arm, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or With Other Aggressive B-Cell Malignancies - AT Institution: Information not provided - AT

Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells (Phase 2-3) - AT Institution: Information not provided - AT

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial (Phase 3) - AT Institution: Information not provided - AT

SADAL: A Phase 2b Open-label, Randomized, Two-arm Study comparing high and low doses of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - AT Allgemeines Krankenhaus der Stadt Wien Klinische Abteilung für Hämatologie und Hämostaseologie

JULIET: A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) - AT Allgemeines Krankenhaus der Stadt Wien Klinische Abteilung für Hämatologie und Hämostaseologie

Phase II single-arm "window-of-opportunity" study of a combination of obinutuzumab (GA-101) and venetoclax (ABT-199) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) Allgemeines Krankenhaus der Stadt Wien Klinische Abteilung für Hämatologie und Hämostaseologie

BEB-trial: A Randomized Phase II Trial Comparing BeEAM With BEAM as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients - AT Hanusch Krankenhaus 3. Medizinische Abteilung (Hämatologie und Onkologie)

A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia - AT St. Anna Kinderspital Zentrum für Kinder- und Jugendheilkunde

A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) - BE Institution: Information not provided - BE

A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma - BE Institution: Information not provided - BE

A Multicenter Open-Label, Phase 1b/2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma- BE Institution: Information not provided - BE

A Phase 2 Study to Evaluate the Efficacy and Tolerability of Debio 1562 (IMGN529) in Combination with Rituximab in Patients with Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin's Lymphoma - BE Institution: Information not provided - BE

A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma - BE Institution: Information not provided - BE

ZUMA-7: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma - BE Cliniques universitaires Saint-Luc - UCLouvain Department of Hematology

PIVeR: A multicentre, phase II, open label, single arm study of pixantrone in patients with CD20-positive relapsed or refractory aggressive non-Hodgkin lymphoma treated with rituximab, ifosfamide and etoposide - BE Cliniques universitaires Saint-Luc - UCLouvain Department of Hematology

GALEN: A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma- BE Cliniques Universitaires UCL de Mont-Godinne Department of Hematology

HOVON 130 NHL: A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U- BE UZ Leuven - Campus Gasthuisberg Department of Hematology

A Randomized Phase II Study of Oral Panobinostat (LBH589) With or Without Rituximab to Treat Relapsed or Refractory Diffuse Large B Cell Lymphoma Hôpital général juif - Jewish General Hospital

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas -FR Institution: Information not provided - FR

A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) - FR Institution: Information not provided - FR

An open label, phase 1/2 study of MEDI-551, a humanized monoclonal antibody directed against CD19, in adult subjects with relapsed or refractory advanced B-cell malignancies - FR CHU de Lyon HCL - GH Sud Service d'hématologie clinique

GALEN : A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma - FR CHRU de Lille - Hôpital Claude Huriez Service des Maladies du sang

Epi-RCHOP : A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) Patients With Poor Prognosis Treated by Rituximab-Cyclophosphamide-Vincristine-Doxorubicin-Prednisolone Chemiotherapy (R-CHOP) CLCC Institut Gustave Roussy Département d'hématologie

A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 in Combination With Obinutuzumab (GA101) in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin's Lymphoma - FR CLCC Institut Gustave Roussy Département d'hématologie

A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292 and Rituximab in Diffuse Large B-cell Lymphoma - FR CLCC Institut Gustave Roussy Institut Gustave Roussy

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials (Phase IV) - FR CLCC Henri Becquerel Service d'Hématologie

SENIOR : Sub-cutaneous Rituximab-miniCHOP Versus Sub-cutaneous Rituximab-miniCHOP + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More. A Multicentric Phase III Study of the LYSA Association - FR CLCC Henri Becquerel Service d'Hématologie

Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study (Phase II) - FR CLCC Institut Bergonié Département d'oncologie médicale - Sarcomes

GATA : A Phase II Trial Evaluating Combination of Atezolizumab, With Venetoclax and Obinutuzumab for Relapsed/Refractory Lymphomas CHU de Montpellier - Hôpital Saint-Eloi Département d'Hématologie clinique

R-CPOP as first line therapy for elderly patients with DLBCL and for patients with limited cardiac function with DLBCL -DE- Universitätsklinikum Freiburg Klinik für Innere Medizin I - Hämatologie, Onkologie und Stammzelltransplantation

ZUMA-7: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma -DE- Universitätsklinikum Heidelberg

CHARLY: Phase-II study on the value of post-transplant Cyclophosphamide after Thiotepa-based haplo-identical stem-cell transplantation for relapsed-refractory lymphoma Zentrum für Innere Medizin (Krehl-Klinik) Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie

A Multicenter Open-Label, Phase 1b/2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma -DE- Universitätsklinikum Ulm

LYMRIT-37-05: A Phase 1 Dose Finding Study of 177Lu-DOTA-HH1 (Betalutin®) in Patients With Relapsed, Diffuse Large B-cell Lymphoma, Not Eligible for Autologous Stem Cell Transplant -DE- Klinikum rechts der Isar der Technischen Universität München

ZUMA-7: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma -DE- CCC Mainfranken an der Universität Würzburg Comprehensive Cancer Center (CCC) Mainfranken

L-MIND: A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) - DE Institution: Information not provided - DE

A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) - DE Institution: Information not provided - DE

ZUMA-7: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma -DE- UKE - Universitätsklinikum Hamburg-Eppendorf

ZUMA-7: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma -DE- Universitätsmedizin Göttingen Klinik für Hämatologie und Medizinische Onkologie

PETAL - study: Positron emission tomography guided therapy of aggressive Non-Hodgkin's Lymphomas (Phase III) Westdeutsches Tumorzentrum Essen (WTZ) Klinik für Hämatologie

A Phase I/II study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with Rituximab in relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL) - DE Universitätsklinikum Münster Medizinische Klinik und Poliklinik A

ZUMA-7: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma -DE- Universitätsklinikum Münster

A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma - IE St James's Hospital Department of Medical Oncology

A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma - IE University Hospital Galway

A phase Ib/II study evaluating the safety and efficacy of MPDL3280A in combination with either obinutuzumab plus bendamustine or obinutuzumab plus CHOP in patients with follicular lymphoma or diffuse large B-cell lymphoma - IT Institution: Information not provided - IT

A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 in Combination With Obinutuzumab (GA101) in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin's Lymphoma - IT Institution: Information not provided - IT

A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) - IT Institution: Information not provided - IT

Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Policlinico S. Orsola-Malpighi - Area S. Orsola Dipartimento di Ematologia e Scienze Oncologiche

PRELUDE: A Phase III Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin Policlinico Umberto I Dipartimento di Biotecnologie Cellulari ed Ematologia

A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) - ES Hospital Universitario Virgen del Rocío

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials (Phase IV) - ES Hospital Universitario Virgen del Rocío Unidad de Hematología

Ofatumumab as Part of the Reduced Intensity Conditioning Regimen (RIC) for Patients With High Risk B Non Hodgkin's Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation (Phase II) Hospital Clínico Universitario de Salamanca Servicio de Hematología

Phase II, randomised, multicentre study with two treatment arms (R-COMP versus R-CHOP) in newly diagnosed elderly patients (?60 years) with non-localised diffuse large B-cell lymphoma (DLBCL)/follicular lymphoma grade IIIb - ES Hospital Clínico Universitario de Salamanca Servicio de Hematología

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials (Phase IV) - ES Hospital Clínico Universitario de Salamanca Servicio de Hematología

A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) - ES Hospital Germans Trias I Pujol

SADAL: A Phase 2b Open-label, Randomized, Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - ES Hospital Clínic de Barcelona Servicio de Hematología

A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) - ES Hospital Universitari Vall d'Hebron

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials (Phase IV) - ES Hospital Universitari Vall d'Hebron Servicio de Hematología y Hemoterapia

First-MIND: Phase Ib, Open-label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) - AT
Institution: Information not provided - AT

ESCALADE: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Subjects <65 Years With Previously Untreated Non-Germinal Center DLBCL - AT
Institution: Information not provided - AT

Phase I, Open Label, Multicenter, Dose Escalation Study of CD19-specific CAR-T Cells in Adult Patients With CLL/SLL and DLBCL - AT
Institution: Information not provided - AT

A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-Cell Lymphoma Post-autologous Hematopoietic Stem-cell Transplantation - BE
UZ Leuven - Campus Gasthuisberg

Department of Hematology

A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART2019.1 in Patients With Relapsed or Resistant CD20 and CD19 Positive B-NHL
Universitätsklinikum Köln

Klinik I für Innere Medizin

R-CHOEP-brut: Ibrutinib and Standard Immuno-Chemotherapy (R-CHOEP-14) in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma (Phase II) DE
Universitätsklinikum Münster

Medizinische Klinik und Poliklinik A

DSHNHL 2004-3 (UNFOLDER 21/14 Study): Phase III randomized study of immunochemotherapy Rituximab-CHOP with or without radiotherapy in patients with aggressive, B-Cell Non-Hodgkin's Lymphoma
Universitätsklinikum des Saarlandes

Klinik für Innere Medizin I

DSHNHL 2004-2 (FLYER): Randomized Phase III Study: 6 x anti-CD20-antibody Rituximab + 6 x CHOP-21 vs. 6 x anti-CD20-antibody Rituximab + 4 x CHOP-21 in patients aged 18-60 years with aggressive CD20 positive B-Cell Lymphoma - DE
Universitätsklinikum des Saarlandes

Klinik für Innere Medizin I

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL) - ES
Institution: Information not provided - ES

ESCALADE: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Subjects <65 Years With Previously Untreated Non-Germinal Center DLBCL - ES
Institution: Information not provided - ES

A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-Cell Lymphoma Post-autologous Hematopoietic Stem-cell Transplantation - CH
Institution: Information not provided - CH

ZUMA-7: A Phase 3, Randomized, Open-Label Study Evaluating Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma - AT
Medizinische Universität Graz

Klinische Abteilung für Hämatologie

SADAL: A Phase 2b Open-label, Randomized, Two-arm Study comparing high and low doses of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - AT
Medizinische Universität Innsbruck

Universitätsklinik für Innere Medizin V - Hämatologie und Onkologie

R-CPOP as first line therapy for elderly patients with DLBCL and for patients with limited cardiac function with DLBCL (phase 2) - AT
Institution: Information not provided - AT

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas - AT
Institution: Information not provided - AT

A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma - AT
Institution: Information not provided - AT

Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 Directed CAR T-Cell Therapy (Phase II-III) - AT
Institution: Information not provided - AT

PORTIA: Phase Ib Study of Tisagenlecleucel in Combination With Pembrolizumab in Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) Patients - AT
Institution: Information not provided - AT

TRANSCENDWORLD: A Phase 2, Single-arm, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or With Other Aggressive B-Cell Malignancies - AT
Institution: Information not provided - AT

Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells (Phase 2-3) - AT
Institution: Information not provided - AT

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial (Phase 3) - AT
Institution: Information not provided - AT

SADAL: A Phase 2b Open-label, Randomized, Two-arm Study comparing high and low doses of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - AT
Allgemeines Krankenhaus der Stadt Wien

Klinische Abteilung für Hämatologie und Hämostaseologie

JULIET: A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) - AT
Allgemeines Krankenhaus der Stadt Wien

Klinische Abteilung für Hämatologie und Hämostaseologie

Phase II single-arm "window-of-opportunity" study of a combination of obinutuzumab (GA-101) and venetoclax (ABT-199) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Allgemeines Krankenhaus der Stadt Wien

Klinische Abteilung für Hämatologie und Hämostaseologie

BEB-trial: A Randomized Phase II Trial Comparing BeEAM With BEAM as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients - AT
Hanusch Krankenhaus

3. Medizinische Abteilung (Hämatologie und Onkologie)

A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia - AT
St. Anna Kinderspital

Zentrum für Kinder- und Jugendheilkunde

A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) - BE
Institution: Information not provided - BE

A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma - BE
Institution: Information not provided - BE

A Multicenter Open-Label, Phase 1b/2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma- BE
Institution: Information not provided - BE

A Phase 2 Study to Evaluate the Efficacy and Tolerability of Debio 1562 (IMGN529) in Combination with Rituximab in Patients with Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin's Lymphoma - BE
Institution: Information not provided - BE

A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma - BE
Institution: Information not provided - BE

ZUMA-7: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma - BE
Cliniques universitaires Saint-Luc - UCLouvain

Department of Hematology

PIVeR: A multicentre, phase II, open label, single arm study of pixantrone in patients with CD20-positive relapsed or refractory aggressive non-Hodgkin lymphoma treated with rituximab, ifosfamide and etoposide - BE
Cliniques universitaires Saint-Luc - UCLouvain

Department of Hematology

GALEN: A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma- BE
Cliniques Universitaires UCL de Mont-Godinne

Department of Hematology

HOVON 130 NHL: A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U- BE
UZ Leuven - Campus Gasthuisberg

Department of Hematology

A Randomized Phase II Study of Oral Panobinostat (LBH589) With or Without Rituximab to Treat Relapsed or Refractory Diffuse Large B Cell Lymphoma
Hôpital général juif - Jewish General Hospital

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas -FR
Institution: Information not provided - FR

A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) - FR
Institution: Information not provided - FR

An open label, phase 1/2 study of MEDI-551, a humanized monoclonal antibody directed against CD19, in adult subjects with relapsed or refractory advanced B-cell malignancies - FR
CHU de Lyon HCL - GH Sud

Service d'hématologie clinique

GALEN : A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma - FR
CHRU de Lille - Hôpital Claude Huriez

Service des Maladies du sang

A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 in Combination With Obinutuzumab (GA101) in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin's Lymphoma - FR
CLCC Institut Gustave Roussy

Département d'hématologie

A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292 and Rituximab in Diffuse Large B-cell Lymphoma - FR
CLCC Institut Gustave Roussy

Institut Gustave Roussy

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials (Phase IV) - FR
CLCC Henri Becquerel

Service d'Hématologie

SENIOR : Sub-cutaneous Rituximab-miniCHOP Versus Sub-cutaneous Rituximab-miniCHOP + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More. A Multicentric Phase III Study of the LYSA Association - FR
CLCC Henri Becquerel

Service d'Hématologie

Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study (Phase II) - FR
CLCC Institut Bergonié

Département d'oncologie médicale - Sarcomes

GATA : A Phase II Trial Evaluating Combination of Atezolizumab, With Venetoclax and Obinutuzumab for Relapsed/Refractory Lymphomas
CHU de Montpellier - Hôpital Saint-Eloi

Département d'Hématologie clinique

R-CPOP as first line therapy for elderly patients with DLBCL and for patients with limited cardiac function with DLBCL -DE-
Universitätsklinikum Freiburg

Klinik für Innere Medizin I - Hämatologie, Onkologie und Stammzelltransplantation

ZUMA-7: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma -DE-
Universitätsklinikum Heidelberg

CHARLY: Phase-II study on the value of post-transplant Cyclophosphamide after Thiotepa-based haplo-identical stem-cell transplantation for relapsed-refractory lymphoma
Zentrum für Innere Medizin (Krehl-Klinik)

Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie

A Multicenter Open-Label, Phase 1b/2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma -DE-
Universitätsklinikum Ulm

LYMRIT-37-05: A Phase 1 Dose Finding Study of 177Lu-DOTA-HH1 (Betalutin®) in Patients With Relapsed, Diffuse Large B-cell Lymphoma, Not Eligible for Autologous Stem Cell Transplant -DE-
Klinikum rechts der Isar der Technischen Universität München

ZUMA-7: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma -DE-
CCC Mainfranken an der Universität Würzburg

Comprehensive Cancer Center (CCC) Mainfranken

L-MIND: A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) - DE
Institution: Information not provided - DE

A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) - DE
Institution: Information not provided - DE

ZUMA-7: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma -DE-
UKE - Universitätsklinikum Hamburg-Eppendorf

ZUMA-7: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma -DE-
Universitätsmedizin Göttingen

Klinik für Hämatologie und Medizinische Onkologie

PETAL - study: Positron emission tomography guided therapy of aggressive Non-Hodgkin's Lymphomas (Phase III)
Westdeutsches Tumorzentrum Essen (WTZ)

Klinik für Hämatologie

A Phase I/II study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with Rituximab in relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL) - DE
Universitätsklinikum Münster

Medizinische Klinik und Poliklinik A

ZUMA-7: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma -DE-
Universitätsklinikum Münster

A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma - IE
St James's Hospital

Department of Medical Oncology

A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma - IE
University Hospital Galway

A phase Ib/II study evaluating the safety and efficacy of MPDL3280A in combination with either obinutuzumab plus bendamustine or obinutuzumab plus CHOP in patients with follicular lymphoma or diffuse large B-cell lymphoma - IT
Institution: Information not provided - IT

A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 in Combination With Obinutuzumab (GA101) in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin's Lymphoma - IT
Institution: Information not provided - IT

A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) - IT
Institution: Information not provided - IT

Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Policlinico S. Orsola-Malpighi - Area S. Orsola

Dipartimento di Ematologia e Scienze Oncologiche

PRELUDE: A Phase III Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin
Policlinico Umberto I

Dipartimento di Biotecnologie Cellulari ed Ematologia

A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) - ES
Hospital Universitario Virgen del Rocío

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials (Phase IV) - ES
Hospital Universitario Virgen del Rocío

Unidad de Hematología

Ofatumumab as Part of the Reduced Intensity Conditioning Regimen (RIC) for Patients With High Risk B Non Hodgkin's Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation (Phase II)
Hospital Clínico Universitario de Salamanca

Servicio de Hematología

Phase II, randomised, multicentre study with two treatment arms (R-COMP versus R-CHOP) in newly diagnosed elderly patients (?60 years) with non-localised diffuse large B-cell lymphoma (DLBCL)/follicular lymphoma grade IIIb - ES
Hospital Clínico Universitario de Salamanca

Servicio de Hematología

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials (Phase IV) - ES
Hospital Clínico Universitario de Salamanca

Servicio de Hematología

A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) - ES
Hospital Germans Trias I Pujol

SADAL: A Phase 2b Open-label, Randomized, Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - ES
Hospital Clínic de Barcelona

Servicio de Hematología

A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) - ES
Hospital Universitari Vall d'Hebron

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials (Phase IV) - ES
Hospital Universitari Vall d'Hebron

Servicio de Hematología y Hemoterapia

A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma (Phase III) - ES
Hospital Universitari Vall d'Hebron

Servicio de Oncología y Hematología Pediátricas

A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia - ES
Hospital Universitari Vall d'Hebron

Servicio de Oncología y Hematología Pediátricas

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials (Phase IV) - ES
Hospital de la Santa Creu i Sant Pau

Servicio de Hematología

Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 directed CAR T-Cell Therapy - ES
Hospital Sant Joan de Déu Barcelona

Servicio de Oncología y Hematología

A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma (Phase III) - ES
Hospital Sant Joan de Déu Barcelona

Servicio de Oncología y Hematología